Trial Profile
A pilot study to assess the influence of drug transporters on brain and organ distribution of erlotinib in humans
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Jun 2019
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Tariquidar
- Indications Bladder cancer; Brain metastases; Ependymoma; Glioblastoma; Gynaecological cancer; Head and neck cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Squamous cell cancer
- Focus Pharmacokinetics; Proof of concept
- 13 Jun 2019 Planned End Date changed from 2 Jun 2018 to 2 Jun 2020.
- 13 Jun 2019 Planned number of patients changed from 77 to 87.
- 16 Mar 2019 Results (n=22) presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics